NetraMark, a wholly owned subsidiary of Nurosene, is providing next-generation AI solutions for pharmaceutical and biotechnology companies.

LEARN MORE ON NETRAMARK.COM

microscope

Increase efficiency, reduce costs and failure rate.

The NetraMark technology helps to de-risk clinical trials by ingesting clinical trial data and creating patient stratification datasets to inform enrichment criteria for future phases.

LEARN MORE ON NETRAMARK.COM

Meet the Team

We’re a team of mathematicians, scientists, doctors, and pharma experts.